| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allergy immunotherapy: the future of allergy treatment
|
Larsen, Jørgen Nedergaard
|
|
2016
|
21 |
1 |
p. 26-37
12 p.
|
artikel
|
| 2 |
An analysis of FDA-approved drugs for cardiovascular diseases
|
Kinch, Michael S.
|
|
2016
|
21 |
1 |
p. 1-4
4 p.
|
artikel
|
| 3 |
A new paradigm for navigating compound property related drug attrition
|
Barton, Patrick
|
|
2016
|
21 |
1 |
p. 72-81
10 p.
|
artikel
|
| 4 |
A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy
|
Chaudhary, Ajay K.
|
|
2016
|
21 |
1 |
p. 38-47
10 p.
|
artikel
|
| 5 |
Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?
|
Hothersall, J. Daniel
|
|
2016
|
21 |
1 |
p. 90-96
7 p.
|
artikel
|
| 6 |
Contents page 2
|
|
|
2016
|
21 |
1 |
p. iii-
1 p.
|
artikel
|
| 7 |
Contents page 1
|
|
|
2016
|
21 |
1 |
p. i-
1 p.
|
artikel
|
| 8 |
Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries
|
Wang, Xueshun
|
|
2016
|
21 |
1 |
p. 118-132
15 p.
|
artikel
|
| 9 |
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
|
Würth, Roberto
|
|
2016
|
21 |
1 |
p. 190-199
10 p.
|
artikel
|
| 10 |
Evading innate immunity in nonviral mRNA delivery: don’t shoot the messenger
|
Devoldere, Joke
|
|
2016
|
21 |
1 |
p. 11-25
15 p.
|
artikel
|
| 11 |
Expanding roles of superoxide dismutases in cell regulation and cancer
|
Che, Meixia
|
|
2016
|
21 |
1 |
p. 143-149
7 p.
|
artikel
|
| 12 |
Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine
|
Trifonova, Oxana
|
|
2016
|
21 |
1 |
p. 103-110
8 p.
|
artikel
|
| 13 |
Going with the flow: harnessing the power of the vasculature for targeted therapy in rheumatoid arthritis
|
Ferrari, Mathieu
|
|
2016
|
21 |
1 |
p. 172-179
8 p.
|
artikel
|
| 14 |
Identifying compound efficacy targets in phenotypic drug discovery
|
Schirle, Markus
|
|
2016
|
21 |
1 |
p. 82-89
8 p.
|
artikel
|
| 15 |
IFN-lambda therapy: current status and future perspectives
|
Lasfar, Ahmed
|
|
2016
|
21 |
1 |
p. 167-171
5 p.
|
artikel
|
| 16 |
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
|
Bootz, Franziska
|
|
2016
|
21 |
1 |
p. 180-189
10 p.
|
artikel
|
| 17 |
In silico assessment of adverse drug reactions and associated mechanisms
|
Ivanov, Sergey M.
|
|
2016
|
21 |
1 |
p. 58-71
14 p.
|
artikel
|
| 18 |
Patent term extension systems differentiate Japanese and US drug lifecycle management
|
Yamanaka, Takayuki
|
|
2016
|
21 |
1 |
p. 111-117
7 p.
|
artikel
|
| 19 |
Phenotypic screening: the future of antibody discovery
|
Gonzalez-Munoz, Andrea L.
|
|
2016
|
21 |
1 |
p. 150-156
7 p.
|
artikel
|
| 20 |
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
|
Wu, Peng
|
|
2016
|
21 |
1 |
p. 5-10
6 p.
|
artikel
|
| 21 |
Smart materials: in situ gel-forming systems for nasal delivery
|
Karavasili, Christina
|
|
2016
|
21 |
1 |
p. 157-166
10 p.
|
artikel
|
| 22 |
Sphingosine-1-phosphate signaling: unraveling its role as a drug target against infectious diseases
|
Arish, Mohd
|
|
2016
|
21 |
1 |
p. 133-142
10 p.
|
artikel
|
| 23 |
Stabilization of protein–protein interaction complexes through small molecules
|
Zarzycka, Barbara
|
|
2016
|
21 |
1 |
p. 48-57
10 p.
|
artikel
|
| 24 |
The ELF Honest Data Broker: informatics enabling public–private collaboration in a precompetitive arena
|
Paillard, Guillaume
|
|
2016
|
21 |
1 |
p. 97-102
6 p.
|
artikel
|
Tijdschrift beschrijving